

BMJ Open Systematic evaluation of patient-reported outcome (PRO) protocol content and reporting in UK cancer clinical trials: the EPiC study protocol

Khaled Ahmed,^{1,2} Derek Kyte,^{1,2} Thomas Keeley,^{1,2} Fabio Efficace,³ Jo Armes,⁴ Julia M Brown,⁵ Lynn Calman,⁶ Chris Copland,⁷ Anna Gavin,⁸ Adam Glaser,⁹ Diana M Greenfield,¹⁰ Anne Lanceley,¹¹ Rachel Taylor,¹² Galina Velikova,¹³ Michael Brundage,¹⁴ Rebecca Mercieca-Bebber,^{1,15} Madeleine T King,¹⁵ Melanie Calvert^{1,2}

To cite: Ahmed K, Kyte D, Keeley T, *et al*. Systematic evaluation of patient-reported outcome (PRO) protocol content and reporting in UK cancer clinical trials: the EPiC study protocol. *BMJ Open* 2016;**6**:e012863. doi:10.1136/bmjopen-2016-012863

► Prepublication history for this paper is available online. To view these files please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2016-012863>).

Received 1 June 2016
Revised 25 August 2016
Accepted 26 August 2016



CrossMark

For numbered affiliations see end of article.

Correspondence to

Dr Derek Kyte;
d.g.kyte@bham.ac.uk

ABSTRACT

Introduction: Emerging evidence suggests that patient-reported outcome (PRO)-specific information may be omitted in trial protocols and that PRO results are poorly reported, limiting the use of PRO data to inform cancer care. This study aims to evaluate the standards of PRO-specific content in UK cancer trial protocols and their arising publications and to highlight examples of best-practice PRO protocol content and reporting where they occur. The objective of this study is to determine if these early findings are generalisable to UK cancer trials, and if so, how best we can bring about future improvements in clinical trials methodology to enhance the way PROs are assessed, managed and reported. Hypothesis: Trials in which the primary end point is based on a PRO will have more complete PRO protocol and publication components than trials in which PROs are secondary end points.

Methods and analysis: Completed National Institute for Health Research (NIHR) Portfolio Cancer clinical trials (all cancer specialities/age-groups) will be included if they contain a primary/secondary PRO end point. The NIHR portfolio includes cancer trials, supported by a range of funders, adjudged as high-quality clinical research studies. The sample will be drawn from studies completed between 31 December 2000 and 1 March 2014 (n=1141) to allow sufficient time for completion of the final trial report and publication. Two reviewers will then review the protocols and arising publications of included trials to: (1) determine the completeness of their PRO-specific protocol content; (2) determine the proportion and completeness of PRO reporting in UK Cancer trials and (3) model factors associated with PRO protocol and reporting completeness and with PRO reporting proportion.

Ethics and dissemination: The study was approved by the ethics committee at University of Birmingham (ERN_15-0311). Trial findings will be disseminated via presentations at local, national and international conferences, peer-reviewed journals and social media

Strengths and limitations of this study

- Our review will assist the scientific community in determining how best to improve the way patient-reported outcomes (PROs) are assessed, managed and reported in future cancer trials.
- Our review will provide original data regarding the potential factors associated with PRO protocol quality and PRO reporting.
- The review will be limited to UK-led studies adopted to the National Institute for Health Research portfolio, which may limit generalisability of the results.
- Our selection criteria may lead to a cohort of studies that are not fully representative of the field as the trials may, on average, be of a higher quality than those found in the field (they are studies that have successfully completed) and they are more likely to be trials that have yielded a positive result (due to publication bias by journals).
- Our search criteria may be more likely to identify and obtain the required documents for non-industry sponsored trials, as the protocols of industry trials may be more likely to be confidential due to commercially sensitive information being included in them.

including the CPROR twitter account and UOB departmental website (<http://www.birmingham.ac.uk/cpro0r>).

Trial registration number: PROSPERO CRD42016036533.

INTRODUCTION

Patient-reported outcome (PRO) measures are validated questionnaires, self-completed by patients, that provide the patient perspective on physical, functional and psychological

consequences of treatment and the degree and impact of disease symptoms.¹ The value of using PROs in cancer clinical trials has been emphasised by major international health-policy and regulatory authorities and by patients with cancer.²⁻⁴ PRO results can inform patient choice and clinician decision-making, health technology assessment, health economic evaluations, labelling claims and healthcare policy and commissioning.⁵⁻⁸

Patients with cancer value PRO information and may use it to inform complex healthcare decisions.^{9 10} For instance, PRO trial results can help patients to assess whether survival benefits of a new drug outweigh potential side effects or may assist patients and their clinicians in choosing between treatment options offering similar survival rates.¹¹⁻¹⁵ Given their importance: (1) details regarding PRO assessment should be included in the trial protocol, to ensure appropriate data collection and management;^{16 17} and (2) PRO results should be fully reported in arising trial publications, to enable timely access by patients, clinicians and policymakers and facilitate integration of findings into clinical practice.¹⁸ However, our recent review of 75 National Institute for Health Research (NIHR) Health Technology Assessment trials¹⁹ suggests important PRO information is frequently omitted from trial protocols, even where a PRO is the primary outcome of the study. This may lead to impaired data collection and result in poor quality PRO data, therefore limiting the potential of PRO findings to effectively inform patient care.²⁰ Furthermore, international research suggests PRO results are poorly reported in trial publications or may not be reported at all.^{18 21 22} Thus, valuable information that may have a significant impact on treatment decision-making and outcomes may not be available to patients, clinicians and researchers. This would represent a waste of limited healthcare and research resources, which is unethical, and also devalues the contribution of trial participants who spend time and effort providing PRO data.²³

This study aims to evaluate the standards of PRO-specific content in UK cancer trial protocols and their arising publications. The specific study objectives are to:

- ▶ Determine the completeness of PRO-specific protocol content in UK cancer trials.
- ▶ Determine the proportion of trials reporting PRO results, that is, the number of trials including PROs in their protocol and subsequently reporting the results in their principal publication.
- ▶ Determine the completeness of PRO reporting.
- ▶ Model factors associated with PRO protocol and reporting completeness, and with PRO reporting proportion.
- ▶ Highlight examples of best-practice PRO protocol content and reporting where they occur.

HYPOTHESES

- ▶ Trials in which the primary end point is based on a PRO will have more complete PRO protocol and publication components than trials in which PROs are secondary end points.

- ▶ Publications of trials with more complete PRO protocol components will have more complete reporting of PROs than those of trials with less complete PRO protocol components.

METHODS AND ANALYSIS

Inclusion and exclusion criteria

Completed NIHR Portfolio Cancer clinical trials (all cancer specialities/age groups) will be included if they contain a primary/secondary PRO end point. The NIHR portfolio includes UK-led trials, supported by a range of funders, adjudged as high-quality clinical research studies.²⁴ The sample will be drawn from studies completed between 31 December 2000 and 1 March 2014 (n=1141) to allow sufficient time for completion of the final trial report and publication (figure 1). Non-randomised trials and trials not completed by the cut-off date (1 March 2014) will be excluded.

Protocol/publication sourcing

Two investigators (TK/KA) will independently search the NIHR Portfolio for eligible trials; disagreements will be resolved through discussion with a third or fourth reviewer (DK/MC). The most up-to-date trial protocol (final version approved by ethics) will be retrieved for review. Following a pilot, it was determined that trial registry information was frequently incomplete, therefore we plan to search for protocols using a range of resources outlined below:

1. NIHR portfolio; ISRCTN
2. EU Clinical Trials Register/EUdract
3. Clinical trials.gov
4. UKNCRN/UK Clinical trials gateway
5. Funder/Sponser
6. Google

For each protocol sourced, we will retrieve all related subsequent reports/publications either via a direct email to the named trial contact or using recognised bibliographic databases (eg, MEDLINE, Embase, CINAHL).

Publications will be sourced via direct contact with the corresponding/first author, or via the Patient-Reported Outcome Measures Over Time In Oncology (PROMOTION) Registry (<http://promotion.gimema.it/>),²⁵ Embase; MEDLINE; Cinahl+; PsycINFO and Cochrane databases.

Data extraction

Two investigators (TK/KA) will independently extract the following data for each included trial, using a pre-designed data extraction form: trial demographics, year of protocol, the name(s)/type(s) of PRO(s) used, whether a PRO was a primary and/or secondary outcome, trial sample size, trial setting (national/international), number of research sites, funding source (including academic and industry supported), cancer specialty and age group (adult, teenage and young adult (TYA, 13–




Figure 1 Schematic breakdown of trial search results of interventional clinical cancer trials between 1 March 2014 and 31 December 2000. PRO, patient-reported outcome.

24 years inclusive), paediatric). The following data will be extracted from included trial reports/publications and recorded on the same form: year of final report/publication(s), number of publications and journal/publication source(s).

Checklists

Completeness of the PRO-specific content of trial protocols will be assessed using a PRO protocol checklist¹⁹ detailing 33 PRO-specific items that are recommended in the literature for inclusion in a trial protocol. Completeness of general sections within each protocol will be assessed using the SPIRIT checklist, as a proxy measure of the overall strength of the protocol.^{17 26} Completeness of PRO reporting will be evaluated using the CONSORT PRO extension checklist.²⁷ We will also explore the use of the ISOQOL reporting standards checklist. General quality of reporting will be assessed by the 37-item 2010 CONSORT checklist.²⁸

Protocol and publication review

Trial protocols and their primary publications (presenting the principal study findings) will be evaluated in the review/analysis. Subsequent trial publications focused on PRO-specific results will also be described. Two investigators (TK/KA) will independently assess the content of the included protocols using the SPIRIT and PRO protocol checklists. The investigators will independently assess consistency of the trial protocol/registration information with all subsequent publications to identify any discrepancies in the reporting of PRO trial outcomes. Unreported outcomes will be defined as those prespecified in the trial protocol/registration information but not reported in any subsequent publications.²⁹ If a report is available, investigators will assess its completeness using the CONSORT and CONSORT-PRO Extension checklists (and the ISOQOL reporting standards checklist if applicable/feasible).³⁰ Levels of investigator agreement will be determined for each checklist. Disagreements will be resolved through discussion with a third investigator (DK/MC).

Quantitative data analysis

Descriptive analyses will be conducted on the number of SPIRIT and PRO checklist items present in the included trial protocols; on the proportion of incomplete PRO reporting and, where appropriate, on the number of CONSORT and CONSORT-PRO Extension checklist items present in the included in the principal trial publication. CONSORT-PRO checklist scores will also be described for those trials with subsequent PRO-specific publications and time from principal publication to secondary PRO publication will be reported.

PRO protocol and reporting models

To explore factors associated with the inclusion of PRO-specific protocol items, we will perform a prespecified multiple regression analysis in which the dependent variable will be the 'PRO protocol checklist score' and the independent variables will be (1) year of protocol, (2) whether the PRO was named as a primary or secondary outcome, (3) cancer specialty, (4) participant age group (adult/TYA/paediatric), (5) trial sample size, (6) funding source and (7) the SPIRIT checklist score. We will also perform a logistic regression, using the same covariates, in which the dependent variable will be 'PRO trial results reported in the principal trial publication (yes/no)'.

To explore factors associated with the inclusion of CONSORT-PRO Extension reporting items, we will perform a prespecified multiple regression analysis in which the dependent variable will be the 'CONSORT-PRO checklist score' and the independent variables will be (1) the year of publication, (2) whether the PRO was named as a primary or secondary outcome, (3) whether there were single or multiple reports, (4) trial sample size, (5) funding source, (6) journal/publication source, (7) the standard CONSORT checklist score, and (8) the PRO protocol checklist score.

Where the sample size allows, we will attempt to conduct parallel exploratory analysis in which trials with a PRO primary end point are analysed separately from those with secondary PRO end points. All models and covariates will be finalised prior to the data analysis phase.

Sample size calculation

A minimum of 80 protocols and publications will be required to satisfy the sample size requirement for the regression analyses (10 per covariate)³¹ of trials regardless of whether PROs are primary or secondary end points.

Ethics and dissemination

The study was approved by the ethics committee at the University of Birmingham (ERN_15-0311) in September 2015. The results of this study will be disseminated via presentations at local, national and international conferences, peer-reviewed journals and through social media including the Centre for Patient Reported Outcomes Research twitter account and the University of Birmingham departmental website (<http://www.birmingham.ac.uk/cpror>), and via the NCRI (including the consumer forum), Macmillan Cancer Support and via international cancer trials groups.

and via the NCRI (including the consumer forum), Macmillan Cancer Support and via international cancer trials groups.

Protocol and registration

The study protocol is registered on PROSPERO (CRD42016036533), and registration details are available at: http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42016036533.

DISCUSSION

A 2015 review investigated the frequency with which PROs (health-related quality of life) were specified in cancer trial protocols (2000–2003, non-UK) and subsequently reported in the literature.²¹ Of the 173 included trials, just over half (n=90) included a PRO, but only 35 of these (38%) reported the findings in an arising publication. However, no evaluation of the quality of PRO protocol/publication content was undertaken, and so the relationship between protocol completeness and reporting could not be assessed.

The current review is therefore necessary to provide a comprehensive representation of the standards of PRO content of protocols in UK cancer clinical trials and to assess whether addressing PRO content in protocols leads to more complete reporting of PROs in subsequent trial publications. Moreover, this systematic review will provide original data regarding the potential factors associated with PRO protocol quality and PRO reporting quality/proportion. This information will assist the scientific community in determining how best we can bring about methodological improvements in the way PROs are assessed, managed and reported in future cancer trials.

Author affiliations

¹Centre for Patient Reported Outcomes Research (CPROR), University of Birmingham, Birmingham, UK

²Institute of Applied Health Research, University of Birmingham, Birmingham, UK

³Health Outcomes Research Unit, Italian Group for Adult Hematologic Diseases (GIMEMA), Rome, Italy

⁴King's College London, London, UK

⁵UKCRC Registered CTU Network, University of Leeds, Leeds, UK

⁶Department of Health Sciences, University of Southampton, Southampton, UK

⁷NCRI Psychosocial Oncology and Survivorship CSG Consumer member, York, UK

⁸Queen's University Belfast, Centre for Public Health, Belfast, UK

⁹Leeds Institute of Cancer & Pathology, University of Leeds, Leeds, UK

¹⁰Sheffield Teaching Hospital NHS Foundation Trust, Sheffield, UK

¹¹University College London, UCL EGA Institute for Women's Health, London, UK

¹²University College London Hospital (UCLH), London, UK

¹³University of Leeds, Leeds, UK

¹⁴Queen's Department of Oncology School of Medicine, Queen's Cancer Research Institute, Kingston, Ontario, Canada

¹⁵Faculties of Science and Medicine, University of Sydney, Sydney, New South Wales, Australia

Contributors The study concept and design was conceived by DK, TK, FE, JA, JMB, LC, CC, AGa, AGI, DMG, AL, RT, GV, MB, RM-B, MTK and MC. TK and KA will conduct screening and analysis with input and supervision from DK

and MC. KA prepared the first draft of the manuscript. DK, TK, FE, JA, JMB, LC, CC, AGa, AGI, DMG, AL, RT, GV, MB, RM-B, MTK and MC all provided edits and critiqued the manuscript for intellectual content.

Funding This study was supported by Macmillan Cancer Support grant number 15200586.

Competing interests JA, LC, CC, AGa, AGI, DMG, DK and AL are all members of the National Cancer Research Institute Psychosocial Oncology and Survivorship CSG subgroup: 'Understanding and measuring the consequences of cancer and its treatment'. FE receives personal fees from TEVA, Seattle genetics and Bristol Myers Squibb and grants from Lundbeck. GV receives grants from the from National Institute for Health Research and Yorkshire Cancer Research and personal fees from Roche, Genentech, Eisai and Novartis. MC receives personal fees from Astellas Pharma and Ferring and chairs the ISOQOL Best Practice for PROs in Trials Taskforce.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: <http://creativecommons.org/licenses/by/4.0/>

REFERENCES

- Dawson J, Doll H, Fitzpatrick R, *et al.* The routine use of patient reported outcome measures in healthcare settings. *BMJ* 2010;340:c186.
- Ahmed S, Berzon RA, Revicki DA, *et al.* The use of patient-reported outcomes (PRO) within comparative effectiveness research: implications for clinical practice and health care policy. *Med Care* 2012;50:1060–70.
- DoH. *Equity and excellence: liberating the NHS*. UK: Department of Health, 2011.
- Ouwens M, Hermens R, Hulscher M, *et al.* Development of indicators for patient-centred cancer care. *Support Care Cancer* 2010;18:121–30.
- FDA. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. 2009. <http://www.fda.gov/downloads/Drugs/Guidance/ComplianceRegulatoryInformation/Guidances/UCM193282.pdf>
- Higginson IJ, Carr AJ. Measuring quality of life: using quality of life measures in the clinical setting. *BMJ* 2001;322:1297–300.
- NICE. Guidance on the use of trastuzumab for the treatment of advanced breast cancer. National Institute for health and care excellence. Technology appraisal guidance [TA34] Published date: 15 March 2002. <https://www.nice.org.uk/guidance/ta34>
- EMA. Reflection paper on the use of patient reported outcome (PRO) measures in oncology studies (Draft). European Medicines Agency 2014; Oncology Working Party; Doc. ref. EMA/CHMP/292464/2014.
- Brundage M, Leis A, Bežjak A, *et al.* Cancer patients' preferences for communicating clinical trial quality of life information: a qualitative study. *Qual Life Res* 2003;12:395–404.
- Davidson BJ, Goldenberg SL, Gleave ME, *et al.* Provision of individualized information to men and their partners to facilitate treatment decision making in prostate cancer. *Oncol Nurs Forum* 2003;30:107–14.
- Au HJ, Ringash J, Brundage M, *et al.* Added value of health-related quality of life measurement in cancer clinical trials: the experience of the NCIC CTG. *Expert Rev Pharmacoecon Outcomes Res* 2010;10:119–28.
- Basch E. Toward patient-centered drug development in oncology. *N Engl J Med* 2013;369:397–400.
- Blazeby JM, Avery K, Sprangers M, *et al.* Health-related quality of life measurement in randomized clinical trials in surgical oncology. *J Clin Oncol* 2006;24:3178–86.
- Ford HE, Marshall A, Bridgewater JA, *et al.* Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. *Lancet Oncol* 2014;15:78–86.
- Dutton SJ, Ferry DR, Blazeby JM, *et al.* Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. *Lancet Oncol* 2014;15:894–904.
- Calvert M, Thwaites R, Kyte D, *et al.* Putting patient-reported outcomes on the 'Big Data Road Map'. *J R Soc Med* 2015;108:299–303.
- Chan A, Tetzlaff JM, Gøtzsche PC, *et al.* SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. *BMJ* 2013;346:e7586.
- Brundage M, Bass B, Davidson J, *et al.* Patterns of reporting health-related quality of life outcomes in randomized clinical trials: implications for clinicians and quality of life researchers. *Qual Life Res* 2011;20:653–64.
- Kyte D, Duffy H, Fletcher B, *et al.* Systematic evaluation of the patient-reported outcome (PRO) content of clinical trial protocols. *PLoS One* 2014;9:e110229.
- Kyte D, Ives J, Draper H, *et al.* Inconsistencies in quality of life data collection in clinical trials: a potential source of bias? Interviews with research nurses and trialists. *PLoS One* 2013;8:e76625.
- Schandelmaier S, Conen K, von Elm E, *et al.* Planning and reporting of quality-of-life outcomes in cancer trials. *Ann Oncol* 2015;26:1966–73.
- Efficace F, Fayers P, Pusic A, *et al.* On behalf of EORTC Quality of Life Group. PROMOTION Registry. Quality of patient-reported outcome reporting across cancer randomized controlled trials according to the CONSORT PRO extension: a pooled analysis of 557 Trials. *Cancer* 2015;121:3335–42.
- Chalmers I, Bracken MB, Djulbegovic B, *et al.* How to increase value and reduce waste when research priorities are set. *Lancet* 2014;383:156–65.
- Nisula S, Yang R, Poukkanen M, *et al.* Predictive value of urine interleukin-18 in the evolution and outcome of acute kidney injury in critically ill adult patients. *Br J Anaesth* 2015;114:460–8.
- PROMOTION. Patient-Reported Outcomes Measurements Over Time In ONcology Fondazione Gimema. 2016 <http://promotion.gimema.it/> (accessed Apr 2016).
- Chan AW, Tetzlaff JM, Altman DG, *et al.* SPIRIT 2013 statement: defining standard protocol items for clinical trials. *Ann Intern Med* 2013;158:200–7.
- Calvert M, Blazeby J, Altman DG, *et al.* Reporting of patient reported outcomes in randomised trials: the CONSORT PRO extension. *JAMA* 2013;309:814–22.
- Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *PLoS Med* 2010;7:e1000251.
- Smyth RM, Kirkham JJ, Jacoby A, *et al.* Frequency and reasons for outcome reporting bias in clinical trials: interviews with trialists. *BMJ* 2011;342:c7153.
- Brundage M, Blazeby J, Revicki D, *et al.* Patient-reported outcomes in randomized clinical trials: development of ISOQOL reporting standards. *Qual Life Res* 2013;22:1161–75.
- Babyak MA. What you see may not be what you get: a brief, nontechnical introduction to overfitting in regression-type models. *Psychosom Med* 2004;66:411–21.